Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VeradigmMDRX +1.87%23 Debt-to-Equity is 0.22 as of Dec. 2022. GuruFocus rates MDRX with a GF Score™ of 23/100. Among 564 Healthcare Providers & Services companies, Veradigm ranks worse than 177304.79% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Veradigm's Debt-to-Equity or its related term are showing as below:
MDRX's Debt-to-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.42 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Veradigm Debt-to-Equity Related Terms
Veradigm Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Veradigm's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDRX vs WEAV, PHR, SOPH: Debt-to-Equity Comparison
For the Health Information Services subindustry, Veradigm's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veradigm Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veradigm's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Veradigm's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veradigm (MDRX) has a Debt-to-Equity of 0.22 as of Dec. 2022. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Veradigm and its competitors. According to the industry distribution chart, Veradigm ranks #999999 out of 564 companies in the Healthcare Providers & Services industry.
Is Veradigm's Debt-to-Equity too high?
Veradigm's current Debt-to-Equity is 0.22. The Healthcare Providers & Services industry median Debt-to-Equity is 0.42. Veradigm's value of 0.22 is 47.6% below this industry median. Based on the distribution chart, Veradigm ranks #999999 out of 564 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Veradigm has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's Debt-to-Equity compare to WEAV and PHR?
According to the Healthcare Providers & Services industry distribution chart, Veradigm ranks #999999 out of 564 companies for Debt-to-Equity. This places Veradigm in the lower half of its industry. The industry median Debt-to-Equity is 0.42. Veradigm's value of 0.22 is 47.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veradigm's current Debt-to-Equity of 0.22 is 47.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Veradigm and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veradigm's current Debt-to-Equity is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (MDRX) has a current Debt-to-Equity of 0.22. The current Debt-to-Equity is 0.22 and 47.6% below the Healthcare Providers & Services industry median of 0.42. Veradigm's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Veradigm (MDRX), the current Debt-to-Equity is 0.22 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
23GF Score
Get the complete analysis for MDRX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDRX has been successfully added to your 
